Suboptimal response to combination therapy with tixagevimab/cilgavimab and remdesivir for persistent SARS-CoV-2 infections in immunocompromised patients.
Tzong-Yow WuPao-Yu ChenJann-Tay WangWang-Da LiuYee-Chun ChenShan-Chwen ChangPublished in: The Journal of antimicrobial chemotherapy (2024)